Business Context and Reporting Period
Company: Neogen Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and nine months ended February 28, 2011
Business Overview: Neogen operates two reportable segments: Food Safety (diagnostic test kits for toxins, bacteria, and allergens) and Animal Safety (animal health products, genetic identification services, and rodenticides). The company is a large accelerated filer incorporated in Michigan.
Key Financial Metrics
| Metric | Three Months Ended Feb 28, 2011 | Nine Months Ended Feb 28, 2011 | Balance Sheet (Feb 28, 2011) |
|---|---|---|---|
| Net Sales | $42.2 million | $129.1 million | N/A |
| Gross Margin | $20.6 million (48.7%) | $65.8 million (51.0%) | N/A |
| Operating Income | $8.1 million (19.1%) | $27.3 million (21.1%) | N/A |
| Net Income | $4.9 million | $16.9 million | N/A |
| Diluted EPS | $0.21 | $0.71 | N/A |
| Cash Flow from Operations | N/A | $24.0 million | N/A |
| Cash and Equivalents | N/A | N/A | $47.6 million |
| Total Assets | N/A | N/A | $209.2 million |
| Total Liabilities | N/A | N/A | $30.8 million |
| Shareholders' Equity | N/A | N/A | $178.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 25% for the quarter and 27% for the nine-month period compared to the prior year.
- Food Safety: Revenues grew 5% (quarter) and 15% (nine months). Growth was driven by Bacteria & General Sanitation products (+20% quarter, +18% nine months) and Food Allergen tests (+16% quarter, +59% nine months), aided by the BioKits acquisition.
- Animal Safety: Revenues surged 53% (quarter) and 42% (nine months). This was primarily due to the GeneSeek acquisition (DNA Testing revenue of $5.0M in the quarter and $14.4M year-to-date, with no comparable prior year revenue) and strong Rodenticide & Disinfectant sales (+49% quarter).
- Margin Compression: Gross margin percentage decreased from 51.6% to 48.7% for the quarter and from 52.5% to 51.0% year-to-date. Management attributes this to the lower average gross margins of the GeneSeek operations and a product mix shift toward Animal Safety.
- Operating Efficiency: Despite lower gross margins, operating income margins improved from 17.0% to 19.1% (quarter) and 19.6% to 21.1% (nine months) due to cost control and the revenue leverage from acquisitions.
- Acquisition Adjustments: The company recorded a charge of $218,000 (quarter) and $618,000 (nine months) related to the increase in fair value of the secondary payment liability for the GeneSeek acquisition.
Guidance, Outlook, and Risks
- Guidance: Neogen does not provide specific forecasts of future performance. Management expects R&D expenses to remain in the 4-5% range of revenues.
- Liquidity: The company maintains a $10 million unsecured revolving line of credit with no amounts drawn as of February 28, 2011. Cash and cash equivalents increased to $47.6 million, up from $22.8 million at the prior fiscal year-end.
- Market Risks:
- Foreign Exchange: Operations in Scotland, Brazil, and Mexico expose the company to currency fluctuations (British Pound, Brazilian Real, Mexican Peso). A weaker U.S. dollar increases revenue value, while a stronger dollar decreases it.
- Weather: Agricultural and food production results are subject to weather conditions, which impact demand for mycotoxin testing and other agricultural products.
- Contingencies: The company is involved in environmental remediation at its Randolph, Wisconsin facility, with an estimated liability of $916,000. No material legal proceedings are expected to impact future results.
Investor Verification Checklist
- Acquisition Impact: Verify the sustainability of revenue growth in the Animal Safety segment, specifically the contribution of the GeneSeek acquisition versus organic growth.
- Margin Trends: Monitor whether gross margin percentages stabilize as the GeneSeek integration matures or if the lower margin profile persists.
- Secondary Payment Liability: Track the fair value adjustments of the GeneSeek secondary payment liability, which impacted net income by $618,000 in the nine-month period.
- Cash Conversion: Confirm the efficiency of working capital management, noting the minimal increase in accounts receivable despite significant revenue growth.
- Foreign Currency Exposure: Assess the impact of U.S. dollar strength on future reported revenues given the company's international operations.